Plain-English translation of NCT05687357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called combined with radiation therapy and chemotherapy given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. Researchers want to see if this combination approach helps more patients achieve a complete response (where cancer cells are no longer detected) at the time of surgery compared to standard treatment. Half of the participants will receive the new medication plus standard therapy, and half will receive standard therapy alone.
Currently, standard treatment for advanced stomach cancer involves radiation and chemotherapy before surgery, followed by more chemotherapy afterward. However, many patients still experience cancer recurrence. This trial is exploring whether adding this new immunotherapy medication can help the body's immune system better fight the cancer and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to one of two groups. One group will receive the new immunotherapy medication by IV infusion along with radiation therapy and chemotherapy pills or IV infusions before surgery; the other group will receive standard radiation and chemotherapy alone. After surgery (4–10 weeks later), both groups will continue treatment with additional chemotherapy and the new medication group will continue receiving the immunotherapy medication for up to 16 additional cycles. The entire treatment course will span several months, involving regular hospital visits for infusions, imaging scans, and blood tests to monitor your health and response to treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China